AB Science S.A. (ABSCF)
| Previous close | 11.90 |
| Open | 11.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.90 - 11.90 |
| 52-week range | 8.65 - 18.88 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 562.26M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
AB Science reports its revenues for the year 2021 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2021 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis under the NOC/c policyPublication of new long-term data showing that masitinib extended survival in amyotrophic lateral sclerosis by 25 months, provided that treatment starts early in disease courseContinuation of the development program
- Globe Newswire
AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN IN COVID-19 Paris, 28 April 2022, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB). This randomized (1:1), open-label, phase 2 study (AB2
- Globe Newswire
Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)
PRESS RELEASE COMMUNICATION FROM AB SCIENCE FOLLOWING THE DECISION OF THE ENFORCEMENT COMMITTEE OF THE FRENCH MARKET REGULATOR (AMF) Paris, 29 March 2022, 7.30pm CET AB Science SA (Euronext - FR0010557264 - AB) acknowledges the decision of the Enforcement Committee of the French market regulator (AMF), which has cleared its Chief Executive Officer, Alain Moussy, in a decision concerning possible insider trading. In its decision of March 24, 2022 published yesterday, the AMF Enforcement Committee
